ARTIMPLANT YEAR-END REPORT JANUARY – DECEMBER 2007

- **Net revenue for the fourth quarter increased to SEK 5.0 million (1.6) and for the year to SEK 16.3 million (5.5)***
- **The net loss for the fourth quarter improved to SEK -2.1 million (-9.5) and for the year to SEK 13.4 million (-56.0)**
- **The net loss for the year, excluding non-recurring items, improved to SEK 11.8 million (-38.9)**
- **Earnings per share for the year improved to SEK -0.23 (-0.95)**
- **Sales of Artelon® CMC Spacer amounted to approximately 3,900 (2,750) units, of which approximately 1,100 (1,050) were during the fourth quarter**
- **Over 6,000 patients were treated with Artelon® implants up to and including 2007**
- **Artelon® Tissue Reinforcement was granted FDA clearance for several new indications**
- **FDA clearance for two new Spacer products**
- **An agreement was signed with Small Bone Innovations for new resurfacing indications for the hand and wrist**

N.B. This is a translation from Swedish. The Swedish version shall always take precedence.

Artimplant will hold a telephone conference on this report on February 22, 2008 at 11am, Central European Time (GMT+1). For further information see www.artimplant.com.

* Figures in brackets refer to the corresponding period last year

Artimplant AB
Hulda Mellgrens gata 5
SE-421 32 Västra Frölunda
SWEDEN

Phone +46 (0)31 746 56 00
Fax +46 (0)31 746 56 60
Web www.artimplant.com
Reg. No. 556404-8394

Domicile: Västra Götaland, Municipality of Gothenburg

Artimplant

Artimplant is a biomaterials company focused on solutions to problems in orthopedic and oral surgery. We restore health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon®, a biomaterial developed by the Company, satisfy clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for the treatment of osteoarthritis in the hands and feet, for shoulder and other soft tissue injuries as well as oral applications. All product development and production is carried on by Artimplant. The Company's products are marketed by established companies and up to now this has been through global license agreements with Artimplant. The Company is developing its operations to secure long-term establishment through a number of market channels, including future establishment through in-house brands on a growing market.

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in the Small Cap segment and in the healthcare sector.

Artimplant's mission

Artimplant's mission is to restore the health of patients by offering medical professionals degradable implants that help the body to heal.

Artimplant's vision

Artimplant's vision is to improve the quality of life for millions of people by helping their bodies to heal.

Financial results

Net sales for the fourth quarter increased to SEK 5.0 million (1.6) and for the year SEK 16.3 million (5.5). A total of 72% of revenue for the year derives from product sales with associated license revenues. The remaining 28% of net sales referred to a one-off license fee of SEK 3.2 million for a new license agreement with Small Bone Innovations (SBI) and milestone payments from SBI in conjunction with FDA clearance for Artelon® STT Spacer and Artelon® CMC Spacer Arthro.

The operating loss for the fourth quarter was SEK 2.6 million (-9.8) and for the year SEK 15.6 million (-57.5).

The net loss for the fourth quarter amounted to SEK 2.1 million (9.5) and for the year SEK 13.4 million (56.0). Excluding non-recurring items, the net loss for the year was SEK 11.8 million (38.9) Non-recurring items refer to severance costs of SEK 1.6 million during the second quarter of 2007 and impairment of product development costs brought forward by SEK 17.1 million during 2006. The net loss for the period has not been affected materially by exchange rate fluctuations. Earnings per share for the year, including non-recurring items, amounted to SEK -0.23 (-0.95).

During the fourth quarter the Company continued to develop product estimate calculations and allocation of joint costs to departments and also adjusted the inventory value according to the new product estimates. The proportion of joint costs allocated to production has increased and the proportion to R&D has decreased. Compared to the previous product estimate calculations, inventory value as at December 31, 2007 increased by of SEK 1.3 million. See also under Accounting Principles.

In October Artimplant cleared the obligation to pay royalties to the holder of the basic patent for the biomaterial platform Artelon® in return for a lump sum payment of SEK 2.8 million. The payment was charged to Artimplant's cash reserves and was recorded as a patent investment during the fourth quarter of 2007. As the agreement was terminated as of January 1, 2007, full-year depreciation was made on this patent investment during the fourth quarter. The full-year depreciation, following set-off against the royalty provisions made for the first three quarters of the year, amounts to SEK 0.4 million.

Investments and cash position

Investments during 2007 totaled SEK 3.8 million (2.3) with SEK 3.2 million (1.1) attributable to investments in intangible assets. SEK 2.8 million of investments in intangible assets referred to the clearance of the royalty agreement with the holder of the basic patent for Artelon®. At the end of the period cash and cash equivalents amounted to SEK 49.2 million (68.7).

Sales of Artelon® products

Since the launch of Artelon® more than 6,000 patients have been treated with Artelon® implants. Sales of Artelon® Spacer to Small Bone Innovations' (SBI) customers increased during 2007 to approximately 3,900 (2,750) units, of which approximately 1,100 (1,050) units were sold during the fourth quarter. There was a certain inventory build-up among SBI's customers before the end of the year.



The sales of Artelon® Spacer during the second and third quarters of 2007 could not come up to Artimplant's expectations. The corrective measures implemented by SBI have begun to take affect with increased sales during the fourth quarter. A new surgical procedure has been launched. It offers more stable fixation, which should ensure less postoperative pain. SBI's rapid market penetration means that more than 700 customers have purchased Artelon® Spacer. The majority have only carried out a few operations and still do not have the full experience required to continuously ensure a positive clinical outcome. Use of Artelon® CMC Spacer is a verified and successful form of treatment for thumb-base osteoarthritis.

During the third quarter SBI introduced Artelon® CMC Spacer Arthro for keyhole surgery and Artelon® STT Spacer on the American market. Artimplant does not expect any large sales volumes for these products until SBI has conducted clinical studies together with surgeons in the USA. SBI estimates that 10% of hand surgeons in the USA use arthroscopic surgery. Compared with the market for osteoarthritis in the STT joint, Artimplant estimates that approximately 25% of the patients who are diagnosed with osteoarthritis in the CMC joint also have osteoarthritis in the STT joint.

In December, SBI acquired the right to the resurfacing concept for the joint applications in the hand and wrist which SBI had not already licensed. The sale gave Artimplant USD 500k in a one-off license fee. The agreement also means that Artimplant, at SBI's expense, will develop Artelon® Spacer for three new joints. Artimplant manufactures the products and payment is made in the form of a fixed part and a variable part. At the same time, an option was signed granting Artimplant the right to sell product registrations for existing Spacer products to SBI for USD 400k.

Marketing of Artelon® Tissue Reinforcement (ATR) started during the fourth quarter of 2006. The product has been cleared as reinforcement for soft tissue injuries. It is sold by Biomet Sports Medicine as SportMesh™. Sales to Biomet customers during 2007 totaled just under 600 units. During the fourth quarter Biomet received a non-exclusive right to sell SportMesh™ for the new indications cleared by the FDA in September 2007. This offers Biomet the opportunity to address a much larger market, which is expected to increase their sales of SportMesh™ markedly. Existing agreement for the rotator cuff application have been re-negotiated in such a way that it is now non-exclusive, which offers Artimplant the opportunity to exploit all product applications for ATR alongside Biomet Sports Medicine.

During the fourth quarter of 2007 Biomet commenced an important clinical post-market study in Belgium. Clinical experience shows that ATR is easy to use and is less dependent on surgical procedure and rehabilitation than Artelon® CMC Spacer. Medical experience from the patients who have been treated with ATR is positive in all applications that have been tested.

Sales growth has been steady despite the lack of published clinical data. The market for ATR is thus considered to be significantly larger than for Artelon® CMC Spacer.

During the autumn Artimplant commenced marketing activities for ATR in Europe. A consultancy agreement has been signed with

Professor Lars Peterson, who together with Artimplant's new sales management team has commenced the build-up of European reference clinics with the aim of creating a scientific and commercial foundation for continued market penetration.

Personnel

Kauko Haapasaari was employed during the year as Vice President Sales & Marketing. Ulf Åkerblom left his position has head of Artimplant USA Inc. As at December 31, 2007, Artimplant had 25 employees (27), of whom 12 (12) were women and 13 (15) were men.

Clearances and product development

In September, Artimplant was granted clearance to market ATR for new indications in the USA. Clearance offers the opportunity to sell the product on a considerably larger market than previously. Examples of new indications which can be marketed are reinforcement of all tendons in the shoulder rotator cuff, tendon injuries around the kneecap, biceps and quadriceps as well as Achilles tendons. Previous clearance in the USA was limited to marketing of the product for a ligament in the shoulder rotator cuff (Supraspinatus). Biomet Sports Medicine thus has the opportunity to market SportMesh™ for rotator cuff injuries, which was not possible previously.

During the second quarter, Artimplant was granted FDA clearance to market two new Spacer products in the USA, Artelon® STT Spacer and Artelon® CMC Spacer Arthro. The products were launched by SBI in the USA during the third quarter.

Artelon® Cosmetic for the augmentation of soft tissue in dental applications was granted ethical clearance in June for two post-market studies. The studies are being run by the Brånemark Clinic in Gothenburg and the Faculty of Odontology at Göteborg University.

During 2007, Artimplant developed a new design for Artelon® Bone Scaffold for bone augmentation in the upper jaw in conjunction with a sinus lift. In co-operation with Swedish clinics ethical approval has been granted to conduct a market study.

Summary of 2007

During 2007, Artelon® Tissue Reinforcement consolidated its position on the orthopedics market. Increased sales of Artelon® CMC Spacer and a reduction in Artimplant's overall cost base have resulted in a significant reduction in the negative cash flow.

The Spacer concept has gained medical acceptance on the market. Further development of the surgical procedure and accentuation of the importance of rehabilitation for newly operated patients has led to sales once again increasing. In December, SBI acquired the right to the resurfacing concept, which regenerates joint surface, in all the joints in the hand and wrist. This underlines the confidence SBI has in Artelon®.

Artelon® Tissue Reinforcement, ATR, functions very well in the first applications. During the autumn, FDA clearance was granted for new indications and we will see the effects during 2008. The license agreement with Biomet Sports Medicine was renegotiated, making it non-exclusive. At the same time, Biomet was granted the right to sell ATR for all approved indications under its brand name SportMesh™. Under the medical leadership of Professor Lars Peterson, Artimplant has commenced work on establishing ATR at a number of reference clinics in Europe.

Prospects for 2008

Thanks to the increase in the clinically documented properties of Artelon® Artimplant has the opportunity to build up the brand more quickly in new product applications.

Artimplant has the following operative direction for 2008:

- Continued increase in sales of Artelon® CMC Spacer and Artelon® Tissue Reinforcement in the USA and Europe.
- New American sales management will be established with focus on introducing Artelon® Tissue Reinforcement at a number of reference clinics in the USA.
- Artelon® Tissue Reinforcement will be introduced at a number of reference clinics in Europe.

- Establishment of sales of Artimplant products through distributors in the Nordic region.
- Development of products for soft tissue reconstruction in the CMF area (Cranio-Maxilliofacial/head and face) will commence.
- A new Spacer product will be developed together with SBI.
- A multicenter study will be commenced for Artelon® MTP Spacer.
- To complete post market studies regarding Artelon® Cosmetic for soft tissue replenishment in dental applications.
- To commence a study regarding Artelon® Bone Scaffold for bone replenishment in the upper jaw.

Artimplant's business operations are based on exploiting the Company's unique biomaterial platform Artelon®. Signing agreements with other parties is a natural, ongoing part of this business. There is considerable interest in Artimplant and the technology the Company controls. The largest orthopedic areas, hip, knee and spine, offer very exciting market potential which has yet to be exploited by Artimplant.

Events after the year-end

There were no events of material significance after the year-end.

Significant risks and uncertainty factors

The Company's significant risks and uncertainty factors are presented in the Board of Directors' Report in the most recent annual report. The Company considers that this presentation also applies to this report with the addition that as Artimplant sales in the USA increase so does the currency exchange risk. No derivatives were used during 2007.

Parent Company

The majority of operations are run through the Parent Company, Artimplant AB. Artimplant USA, Inc. is the Company's only subsidiary and is at present fully funded by the Parent Company. The Parent Company's revenue, investments and cash position during 2007 correspond in all material respects to those of the Group. See summary of the Parent Company Income Statement and Balance Sheet on page 10-11.

Accounting principles

Artimplant applies IFRS. This interim report has been prepared in accordance with IAS 34 and the Swedish Annual Accounts Act. The Parent Company's financial statements are prepared in accordance with RR32:06.

As of 2007, the Company does not capitalize product development costs, since difficulty predicting future revenue streams is part of the nature of the business.

During 2006, Artimplant developed its production facilities to meet the increased demand for Artelon® products. As of 2007, the cost of goods and services sold includes a share of the fixed cost of the production facility in addition to variable production costs. This also applies to the product estimate calculations that form the basis for inventory valuation, although this adjustment was made for the first time in the fourth quarter of 2007. In addition, as part of the process of improving its product estimate calculations, the Company updated the allocation of joint costs to departments. The largest change is that a larger proportion of cost of premises has been allocated to production and a smaller proportion to R&D.

Forthcoming reports

Three-monthly report…….. May 6, 2008
Six-monthly report…….. August 7, 2008
Nine-monthly report……..November 11, 2008
Year-end report……February 20, 2009

Financial reports are available on the Company's website www.artimplant.com and are also distributed to the media. For information regarding the business model, technology and products, see Artimplant's Annual Report 2006, which is available on the Company's website.

Annual meeting of stockholders

The annual meeting will be held at 5pm on May 6, 2008 at the Company's head office at Hulda Mellgrens gata 5, SE-421 32 Västra Frölunda, Sweden. The premises will be opened for registration at 4pm. Stockholders who wish to participate must, no later than April 28 2008, register their participation with the Company in one of the following ways:

- By e-mail at agm2008@artimplant.com
- By fax on +46 31-746 56 60,
- By telephone on +46 31-746 56 00,
- By writing to Artimplant AB, Annual Meeting 2008, Hulda Mellgrens gata 5, SE-421 32 Västra Frölunda, Sweden

Notification should include name, civic registration number or company registration number, address, phone number and stockholding as recorded in the stockholders' register on April 28, 2008. To be entitled to attend and vote, stockholders' names must be recorded in the register maintained by VPC AB. Stockholders whose shares are recorded in the names of nominees through a bank or similar institution must request to have their holdings temporarily re-registered in their own names in the stockholders' register by April 28, 2008, in order to be entitled to participate at the meeting. Such notification should take place well before that date. The Company will publish its Annual Report on its website no later than April 22, 2008, and copies will be available at its office.

The Board of Directors proposes that no dividend be distributed for 2007.

For further information please contact

Hans Rosén, Chief Executive Officer
Tel + 46 31 746 56 44, +46 708 583 470
hans.rosen@artimplant.com

Lars-Johan Cederbrant, Chief Financial Officer
Tel. +46 31 746 56 54, +46 703 016 854
lars-johan.cederbrant@artimplant.com

CONSOLIDATED INCOME STATEMENTS

Amounts in SEK thousand	Okt-Dec 2007	Jan-Dec 2007	Okt-Dec 2006	Jan-Dec 2006
Net sales	5,042	16,275	1,645	5,536
Cost of goods and services sold	-477	-2,603	-380	-616
Gross profit/loss	**4,565**	**13,672**	**1,265**	**4,920**
Research and development costs (1,2)	-3,031	-14,722	-5,945	-43,177
Selling costs	-2,067	-9,134	-3,161	-12,090
Administrative costs	-2,128	-5,446	-1,974	-7,183
Operating loss	**-2,661**	**-15,630**	**-9,816**	**-57,530**
Interest income and other financial income	567	2,251	484	1,841
Interest expenses and other financial expenses	-8	-71	-159	-330
Net financial items	**559**	**2,180**	**325**	**1,511**
Loss after financial items	**-2,102**	**-13,450**	**-9,491**	**-56,019**
Taxes	-	-	-	-
Loss for the period	**-2,102**	**-13,450**	**-9,491**	**-56,019**
Earnings per share, SEK	-0.04	-0.23	-0.16	-0.95
Earnings per share after full dilution, SEK	-0.04	-0.23	-0.16	-0.95

The income statements include depreciation on tangible fixed assets and amortization on intangible fixed assets as shown in the following table.

Amounts in SEK thousand	Okt-Dec 2007	Jan-Dec 2007	Okt-Dec 2006	Jan-Dec 2006
(1) Capitalized R&D cost*	546	2,184	546	21,236
(2) Patents	660	1,053	212	779
Machinery and equipment	179	671	203	669
Total depreciation	**1,385**	**3,908**	**961**	**22,685**

** Impairment of capitalized R&D costs of SEK 17,118 thousand is included in Jan-Dec 2006.*

ALLOCATION OF NET SALES

Amounts in SEK thousand Source of revenue	Okt-Dec 2007	Jan-Dec 2007	Okt-Dec 2006	Jan-Dec 2006
Licensing of product applications	945	5,198	585	1,031
Product sales	854	6,523	1,025	3,273
Milestone payments for product development projects	3,243	4,554	35	1,231
	5,042	**16,275**	**1,645**	**5,536**

Geographic areas	Okt-Dec 2007	Jan-Dec 2007	Okt-Dec 2006	Jan-Dec 2006
Scandinavia	280	891	158	717
USA	4,762	15,384	1,487	4,819
	5,042	**16,275**	**1,645**	**5,536**

CONSOLIDATED BALANCE SHEETS

Amounts in SEK thousand	12/31/2007	12/31/2006
ASSETS		
Capitalized product development	5,009	7,193
Patents	3,087	1,131
Total intangible fixed assets	8,096	8,324
Machinery and equipment	1,910	1,890
Total tangible fixed assets	1,910	1,890
Total fixed assets	**10,006**	**10,214**
Raw materials, semi-finished and finished goods	4,373	903
Total inventories, etc.	4,373	903
Accounts receivable	3,538	417
Other receivables	1,092	1,570
Prepaid expenses and accrued income	1,363	1,270
Total short-term receivables	5,993	3,256
Cash and bank accounts	49,240	68,704
Total current assets	**59,606**	**72,863**
TOTAL ASSETS	**69,612**	**83,077**

Amounts in SEK thousand	12/31/2007	12/31/2006
SHAREHOLDERS' EQUITY & LIABILITIES		
Equity		
Share capital	5,924	5,924
Premium reserve	71,989	127,042
Total restricted equity	77,913	132,966
Retained loss / Retained earnings	-210	557
Translation difference	-3	110
Loss for the period	-13,450	-56,019
Total retained loss	-13,664	-55,352
Total equity	**64,249**	**77,614**
Provisions	**52**	**353**
Accounts payable	948	1,212
Other current liabilities	1,651	951
Accrued expenses and prepaid income	2,712	2,947
Total current liabilities	**5,311**	**5,110**
TOTAL SHAREHOLDERS' EQUITY & LIABILITIES	**69,612**	**83,077**

Artimplant
Degradable Materials for Optimal Tissue Repair

CHANGES IN SHAREHOLDERS' EQUITY DURING THE PERIOD

Amounts in SEK thousand	Jan-Dec 2007	Jan-Dec 2006
Share capital	**5,924**	**5,924**
Other capital reserves at the beginning of the period	127,042	162,738
Allocation as resolved by AGM	-55,263	-35,696
Regained VAT	329	-
Reclassification	-119	-
Total other capital reserves	**71,989**	**127,042**
Retained loss at the beginning of the period	-55,352	-35,696
Allocation as resolved by AGM	55,263	35,696
Reclassification	119	-
Benefit employee stock option (IFRS2)	-241	460
Regained VAT	0	97
Translation difference	-3	110
Loss for the period	-13,450	-56,019
Total retained loss	**-13,664**	**-55,352**
Equity at the period-end	**64,249**	**143,379**

CONSOLIDATED CASH FLOW ANALYSES

Amounts in SEK thousand	Jan-Dec 2007	Jan-Dec 2006
Operating activities		
Net loss after financial items	-13,450	-56,019
Adjustment for items not effecting cash flow	3,825	23,477
Cash flow from operating activities before changes in working capital	**-9,625**	**-32,542**
Cash flow from changes in working capital		
Changes in inventories	-3,470	41
Changes in receivables	-2,737	-684
Changes in liabilities	201	-5
Cash flow from operating activities	**-15,632**	**-33,190**
Investing activities		
Acquisition of intangible fixed assets	-3,236	-1,126
Acquisition of tangible fixed assets	-627	-1,165
Sale of tangible fixed assets	30	-
Cash flow from investment activities	**-3,832**	**-2,292**
Financing activities		
Share issue	-	-
Cash flow from financing activities	**-**	**-**
Cash flow for the period	**-19,464**	**-35,482**
Cash and cash equivalents at beginning of period	**68,704**	**104,186**
Cash and cash equivalents at the period-end	**49,240**	**68,704**

KEY RATIOS

	Okt-Dec 2007	Jan-Dec 2007	Okt-Dec 2006	Jan-Dec 2006
Earnings per share, SEK	-0.04	-0.23	-0.16	-0.95
Earnings per share after full dilution, SEK	-0.04	-0.23	-0.16	-0.95
Equity per share, SEK	1.08	1.08	1.31	1.31
Equity per share after full dilution, SEK	1.08	1.08	1.31	1.31
No. of shares at the period-end	59,244,790	59,244,790	59,244,790	59,244,790
Average no. of shares	59,244,790	59,244,790	59,244,790	59,244,790
No. of shares after full dilution	60,446,582	60,446,582	60,348,628	60,348,628
Yield on equity, %	neg	neg	neg	neg
Yield on capital employed, %	neg	neg	neg	neg
Equity/assets ratio, %	92	92	93	93

PARENT COMPANY INCOME STATEMENTS

Amounts in SEK thousand	Okt-Dec 2007	Jan-Dec 2007	Okt-Dec 2006	Jan-Dec 2006
Net sales	5,043	16,240	1,645	5,536
Cost of goods and services sold	-477	-2,603	-381	-616
Gross profit/loss	**4,566**	**13,637**	**1,264**	**4,920**
Research and development costs (1,2)	-3,031	-14,722	-5,999	-43,231
Selling costs	-2,005	-9,202	-3,064	-10,537
Administrative costs	-2,020	-5,370	-1,983	-7,192
Operating loss	**-2,490**	**-15,657**	**-9,782**	**-56,040**
Net financial items	**546**	**2,180**	**-1,087**	**100**
Loss after financial items	**-1,944**	**-13,477**	**-10,869**	**-55,940**
Appropriations	-	-	76	76
Taxes	-	-	-	-
Loss for the period	**-1,944**	**-13,477**	**-10,793**	**-55,864**

The income statements include depreciation on tangible fixed assets and amortization on intangible fixed assets as shown in the following table.

Amounts in SEK thousand	Okt-Dec 2007	Jan-Dec 2007	Okt-Dec 2006	Jan-Dec 2006
(1) Capitalized R&D cost*	546	2,184	546	21,236
(2) Patents	660	1,053	212	779
Machinery and equipment	177	666	202	666
Total depreciation	**1,383**	**3,903**	**960**	**22,681**

** Impairment of capitalized R&D costs of SEK 17,118 thousand is included in Jan-Dec 2006.*

PARENT COMPANY BALANCE SHEETS

Amounts in SEK thousand	12/31/2007	12/31/2006
ASSETS		
Total intangible fixed assets	8,096	8,324
Total tangible fixed assets	1,901	1,879
Stock and participation in subsidiaries	10	10
Total fixed assets	**10,007**	**10,213**
Total current assets	**59,500**	**72,770**
TOTAL ASSETS	**69,506**	**82,982**

Amounts in SEK thousand	12/31/2007	12/31/2006
SHAREHOLDERS' EQUITY & LIABILITIES		
Total equity	**64,195**	**77,583**
Provisions	**52**	**353**
Accounts payable	942	1,196
Liabilities, subsidiaries	534	-
Other current liabilities	1,608	903
Accrued expenses and prepaid income	2,175	2,947
Total current liabilities	**5,259**	**5,046**
TOTAL SHAREHOLDERS' EQUITY & LIABILITIES	**69,506**	**82,982**

The Board of Directors and the CEO certify that this Year-End Report provides a true and fair overview of the Company's and the Group's operations, financial position and results and presents the material risks and uncertainty factors facing the Company and the companies which form part of the Group.

Gothenburg, February 22, 2008
Artimplant AB (publ)

Ingemar Kihlström Chairman of the Board	Hans Rosén President	Rickard Söderberg Board Member
Lennart Ribohn Board Member	Wenche Rolfsen Sandsborg Board Member	Anna Malm Bernsten Board Member

This report has not been reviewed by the Company's auditors.

This information is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on February 22, 2008 at 8:45am (GMT+1).

History

1986 – 1996 – A medical need is identified and the development of a new biomaterial commences. During subsequent years material, product and production development takes place and the technology is verified through preclinical trials.

1997 - The Company acquires a Swedish patent for Artelon® hydrolyzable fiber polymers for use in temporary implants. The Company is floated on the Stockholm Stock Exchange. The first cruciate ligament (ACL) operations on human patients using implants from Artimplant are carried out within the framework of a pilot study.

1998 - The Company acquires Gothenburg Medical Center, a clinic specializing in sports-related injuries.

1999 - Pilot studies in the treatment of damaged thumb ligament and thumb base osteoarthritis are initiated. Artimplant's first multicenter trial in ACL reconstruction begins. Artimplant begins cooperation with Mölnlycke Health Care AB in the field of wound care.

2000 - The first multicenter trial in ACL reconstruction is concluded. The second multicenter ACL reconstruction trial begins. Artimplant's Artelon® patent is approved in the USA and Europe. The marketing organization is expanded.

2001 - Artimplant's quality assurance system is certified by Lloyds Register Quality Assurance. Artimplant's first product, the Artelon® Augmentation Device ACL is granted CE-certification and can now be marketed in Europe. The task of building up the Company's own marketing and sales organization ceased during the autumn. Products and material technology will be commercialized through the granting of licenses to leading companies with a global presence.

2002 - Agreement on wound care signed with Mölnlycke Health Care AB. An extensive restructuring program is commenced to reduce the Company's cost base.

2003 – The Company signs an agreement with Atlantech for sales in the UK of its Artelon® Augmentation Device ACL. Artimplant's Artelon® CMC Spacer for treating thumb base osteoarthritis receives clearance for marketing in Europe. Artelon® Surgical Suture is given clearance by the FDA for sales on the American market. The subsidiary Gothenburg Medical Center is sold.

2004 - Artelon® CMC Spacer receives clearance for marketing from the FDA for sales on the US market. Licensing agreements signed with Small Bone Innovations. A licensing agreement is signed with Biomet Inc. for the production of SportMesh™. Cooperation with Atlantech for the sale of Artelon® Augmentation Device ACL is concluded. Cooperation between Artimplant and Mölnlycke Health Care within wound care is concluded.

2005 - Four new licensing and development agreements are signed with Small Bone Innovations. A distribution agreement for Artelon® Surgical Suture in North America is signed with ArthroCare. Artelon® implant for reinforcing rotator cuffs is cleared for marketing in Europe. Office opened in the United States.

2006 - The Company receives clearance for marketing by the FDA for the sale of the SportMesh™ rotator cuff implant in the USA. Four new Spacer products for the treatment of osteoarthritis in the hand and foot are granted clearance for marketing in Europe. The product Artelon® Augmentation Device ACL is discontinued. The sale of Artelon® CMC Spacer to end-customers increases by over 600% compared with 2005. Over 3,000 patients have been given an Artelon® implant at 500 clinics.